Theratechnologies Inc. is a biopharmaceutical firm dedicated to creating and marketing a range of treatments aimed at fulfilling critical medical requirements across the United States, Canada, and Europe. Its current product portfolio includes EGRIFTA and EGRIFTA SV, designed to diminish excessive abdominal fat in HIV-positive individuals experiencing lipodystrophy. Additionally, it markets Trogarzo, an injectable formulation of ibalizumab, which targets multidrug-resistant HIV-1 infections. Within its development pipeline are F8 Formulation, intended for addressing lipodystrophy in people with HIV; TH1902, currently undergoing Phase 1/Part A clinical trials for triple-negative breast cancer; and TH1904, aimed at treating ovarian cancer. Established in 1993, the company maintains its main office in Montreal, Canada.